| Symbol | MATPF |
|---|---|
| Name | MAAT PHARMA SA |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | 69007 France 70 Avenue Tony Garnier |
| Telephone | +33 (0) 616 48 9250 |
| Fax | — |
| — | |
| Website | https://www.maatpharma.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | — |
| Description | MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. Additional info from OTC: |
No news found.